« Return to News | Drug Sponsors

EMD Millipore inks exclusive agreement with Julphar Diabetes for insulin

Wednesday, August 8, 2012 11:02 AM

EMD Millipore, the life science division of Merck KGaA, has announced an exclusive agreement to sell recombinant human insulin manufactured by Julphar Diabetes, a pharmaceutical production company based in the United Arab Emirates.

The insulin is of non-animal origin and will be marketed under EMD Millipore’s CellPrime brand name, complementing the company’s range of non-animal origin supplements for cell culture biomanufacturing.

“CellPrime Insulin will help the biopharmaceutical industry enhance cell culture performance without sacrificing safety,” said Burghard Freiberg, senior vice president of pharm chemicals solutions. “Owing to its non-animal origin, its consistent manufacturing process and the traceability of its raw materials it enables manufacturers of monoclonal antibodies and recombinant biologics to use an insulin supplement that is both safe and effective.”

EMD Millipore chose Julphar Diabetes as its source for recombinant human insulin because the company has extensive experience in the production of pharmaceutical grade materials, currently manufacturing more than 800 drugs with distribution in 40 countries. The Julphar manufacturing process complies with current pharmacopeial standards and is animal-origin-free which helps ensure batch-to-batch consistency. 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.